#off-label marketing

[allisonlegal]

Abbott Labs Settles Off-Label Marketing Allegations

United States Attorney William M. McSwain announced today that pharmaceutical companies Abbott Laboratories and AbbVie Inc. (“Abbott”) will pay $25 million to resolve allegations that it employed kickbacks and unlawful methods of marketing and promotion to induce physicians to prescribe the drug TriCor®. The settlement resolves allegations that, between 2006 and 2008, Abbott knowingly paid…

Abbott Labs Settles Off-Label Marketing Allegations was originally published on Allison Legal Law Firm

[allisonlegal]

Lawsuit Claims AstraZeneca Pushed Off-Label Drugs

AstraZeneca Plc is in talks to settle a Texas lawsuit claiming that the company fleeced the state’s Medicaid program by fraudulently marketing one of its top drugs, according to court filings. Texas sued the drugmaker in 2013, saying AstraZeneca had targeted the state’s Medicaid program by urging doctors to prescribe the powerful antipsychotic Seroquel for…

Lawsuit Claims AstraZeneca Pushed Off-Label Drugs was originally published on Allison Legal Law Firm

[allisonlegal]

Recognizing and Preventing Medical Device Fraud

Sales and marketing tactics used by medical device companies, such as off-label marketing and consulting or speaking agreements with physicians, could violate the False Claims Act and leave providers liable for claims billed to Medicare and Medicaid. A 2014 HHS Office of the Inspector General (OIG) audit found hospitals routinely get Medicare to reimburse for pacemakers…

Recognizing and Preventing Medical Device Fraud was originally published on Allison Legal Law Firm

[allisonlegal]

Biotech Exec Fights to Dismiss Illegal Marketing Case

Bill Facteau made millions of dollars by selling a company that sold devices to treat sinus infections. But after the government accused him of questionable marketing practices surrounding one device, the Atherton biotech executive landed in federal court. Now his cautionary story has turned into a closely watched legal appeal that has consumer advocates, industry leaders and…

Biotech Exec Fights to Dismiss Illegal Marketing Case was originally published on Allison Legal Law Firm

[medprocomp]

Novartis Pays $35 Million to Settle False Claims Case

Novartis Pharmaceuticals Corporation has paid more than $35 million to resolve federal and state False Claims Act allegations resulting from the off-label marketing for Elidel. Elidel is a cream approved by the Food and Drug Administration to treat eczema in patients older than two when conventional therapy is ineffective “or not advisable,” and only for…

Novartis Pays $35 Million to Settle False Claims Case was originally published on

[medprocomp]

Abbott Labs Could Face $1B Whistleblower Fine for Off-Label Use of Stents

Abbott Laboratories could face a $1 billion fine in a federal whistle-blower lawsuit over off-label use of stents, and allegations of Medicare fraud and kickbacks paid to hospitals and physicians for such use. The jury trial began this week in U.S. District Court for the Northern District of Texas in Dallas, 10 years after former…

Abbott Labs Could Face $1B Whistleblower Fine for Off-Label Use of Stents was originally published on

[allisonlegal]

Abbott Labs Could Face $1B Whistleblower Fine

Abbott Laboratories could face a $1 billion fine in a federal whistle-blower lawsuit over off-label use of stents, and allegations of Medicare fraud and kickbacks paid to hospitals and physicians for such use. The jury trial began this week in U.S. District Court for the Northern District of Texas in Dallas, 10 years after former…

Abbott Labs Could Face $1B Whistleblower Fine was originally published on Allison Legal Law Firm

[howleygreen-blog]

The federal government recovered more than $4.3 billion from companies and individuals who were accused of healthcare fraud last year. Of that amount, $3.75 billion – or 87% of the total – was recovered from pharmaceutical companies.